Guideline Atlas

Glomerulonephritis

Also known as: GN · IgA nephropathy · nephritic syndrome

Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.

United StatesNKF/AUA
CurrentGlobal guideline

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

KDIGO · 2021 · 2021 (updated chapter-by-chapter)

This guideline covers diagnosis and treatment of the major primary and secondary glomerular diseases, with an opening chapter on management principles common to all of them. KDIGO is revising it one chapter at a time rather than reissuing it whole.

  • KDIGO describes the 2021 guideline as its most extensive to date, organised into eleven chapters covering general management principles plus individual glomerular diseases. source
  • Chapters already replaced by standalone updates include lupus nephritis (2024), ANCA-associated vasculitis (2024), nephrotic syndrome in children (2025) and IgA nephropathy (2025). source
EuropeERA/EAU (global: KDIGO)
CurrentGlobal guideline

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

KDIGO · 2021 · 2021 (updated chapter-by-chapter)

This guideline covers diagnosis and treatment of the major primary and secondary glomerular diseases, with an opening chapter on management principles common to all of them. KDIGO is revising it one chapter at a time rather than reissuing it whole.

  • KDIGO describes the 2021 guideline as its most extensive to date, organised into eleven chapters covering general management principles plus individual glomerular diseases. source
  • Chapters already replaced by standalone updates include lupus nephritis (2024), ANCA-associated vasculitis (2024), nephrotic syndrome in children (2025) and IgA nephropathy (2025). source

US vs EU key differences

No curated US/EU comparison yet for this disease.

What changed recently

  1. GLOBAL201220212021-10-01

    The 2021 guideline covered complement-mediated glomerular disease for the first time and incorporated newer targeted and immunosuppressive agents unavailable in 2012. For lupus nephritis it cut the cumulative intravenous methylprednisolone dose and moved to a lower, more rapidly tapered oral prednisone start.

    source ↗curation confidence 90%

See the full update feed for changes across every system.